WO2025101862 - SINGLE DOMAIN ANTIBODY BINDERS OF MYC
National phase entry is expected:
Publication Number
WO/2025/101862
Publication Date
15.05.2025
International Application No.
PCT/US2024/055071
International Filing Date
08.11.2024
Title **
[English]
SINGLE DOMAIN ANTIBODY BINDERS OF MYC
[French]
LIANTS D'ANTICORPS À DOMAINE UNIQUE DE MYC
Applicants **
AXELYF EHF.
WITTRUP, Karl, Dane
Inventors
LI, Heng
POP, Marius, S.
WILFONG, Christopher, M.
WIJAYA, Juwina
BENENATO, Kerry, E.
LUNDE, Bradley
DESAI, Alec
Priority Data
63/597,283
08.11.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3434 | |
| EPO | Filing, Examination, Granting | 14931 | |
| Japan | Filing, Examination, Granting | 2264 | |
| South Korea | Filing, Examination, Granting | 2236 | |
| USA | Filing, Examination, Granting | 12090 |
Total:
34,955
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are polypeptides comprising or consisting of anti-Myc single domain antibodies (sdAd), as well as bifunctional and dual-specific bifunctional polypeptides incorporating the anti-Myc sdAbs that induce degradation of a first and optionally a second biological target through the cellular proteasome mechanism. The disclosed bifunctional polypeptides generally comprise a first targeting moiety that includes the anti-Myc sdAb, and a second component that has ubiquitination function, and optionally a second targeting moiety targeting at least a second target protein. The binding of Myc by the first targeting moiety promotes ubiquitination of Myc by the second component, thereby labeling the Myc for proteasomal degradation. These bifunctional polypeptides may be used for the treatment of a disease in a subject, where the first and/or second targeting moieties bind a biological target(s) whose abnormal function and/or expression is associated with the disease.[French]
L'invention concerne des polypeptides comprenant ou constitués d'anticorps à domaine unique anti-Myc (sdAd), ainsi que des polypeptides bifonctionnels et bifonctionnels à double spécificité incorporant les sdAbs anti-Myc qui induisent la dégradation d'une première et éventuellement d'une seconde cible biologique à travers le mécanisme de protéasome cellulaire. Les polypeptides bifonctionnels selon l'invention comprennent généralement une première fraction de ciblage qui comprend l'anti-Myc sdAb, et un second composant qui a une fonction d'ubiquitination, et éventuellement une seconde fraction de ciblage ciblant au moins une seconde protéine cible. La liaison de Myc par la première fraction de ciblage favorise l'ubiquitination de Myc par le second composant, ce qui permet de marquer le Myc pour la dégradation protéasomale. Ces polypeptides bifonctionnels peuvent être utilisés pour le traitement d'une maladie chez un sujet, le premier et/ou le second composant se liant à une ou plusieurs cibles biologiques dont la fonction et/ou l'expression anormales est associée à la maladie.